Group 1: Earnings Performance - Steelcase reported quarterly earnings of $0.20 per share, exceeding the Zacks Consensus Estimate of $0.12 per share, and up from $0.16 per share a year ago, representing an earnings surprise of +66.67% [1] - The company posted revenues of $779 million for the quarter ended May 2025, surpassing the Zacks Consensus Estimate by 3.05%, compared to year-ago revenues of $727.3 million [2] - Over the last four quarters, Steelcase has surpassed consensus EPS estimates four times and topped consensus revenue estimates three times [2] Group 2: Stock Performance and Outlook - Steelcase shares have declined approximately 8.4% since the beginning of the year, while the S&P 500 has gained 3.6% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the coming quarter is $0.40 on revenues of $879.9 million, and for the current fiscal year, it is $1.04 on revenues of $3.25 billion [7] Group 3: Industry Context - The Business - Office Products industry, to which Steelcase belongs, is currently in the top 5% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Steelcase's stock performance [5][6]

Core Viewpoint - Evercore (EVR) presents a strong investment opportunity due to its improving earnings outlook and analysts' increasing earnings estimates [1][2] Earnings Estimate Revisions - Analysts have shown growing optimism regarding Evercore's earnings prospects, reflected in the upward trend of estimate revisions, which typically correlates with stock price movements [2] - The consensus earnings estimate for the current quarter is $1.49 per share, a decrease of 17.68% from the previous year, but has increased by 6.07% over the last 30 days due to one upward revision [6] - For the full year, the expected earnings are $11.41 per share, representing a 21.13% increase from the prior year, with a 5.8% increase in consensus estimates over the past month [7][8] Zacks Rank and Performance - Evercore has achieved a Zacks Rank 1 (Strong Buy), indicating strong potential for outperformance based on earnings estimate revisions [9] - Historically, Zacks 1 Ranked stocks have generated an average annual return of +25% since 2008, suggesting a favorable investment environment for Evercore [3] Stock Performance - The stock has appreciated by 13.1% over the past four weeks, indicating positive market sentiment and potential for further upside [10]

Core Viewpoint - Veeva Systems (VEEV) has received an upgrade to a Zacks Rank 1 (Strong Buy) due to an upward trend in earnings estimates, indicating a positive outlook for the company's stock price [1][4]. Earnings Estimates and Ratings - The Zacks rating system is primarily based on a company's changing earnings picture, specifically the Zacks Consensus Estimate for EPS from sell-side analysts [2]. - A strong correlation exists between changes in earnings estimates and near-term stock price movements, making the Zacks rating system valuable for investors [3][5]. - The recent upgrade for Veeva reflects optimism about its earnings outlook, which could lead to increased buying pressure and a rise in stock price [4][6]. Performance of Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 stocks historically generating an average annual return of +25% since 1988 [8]. - The system maintains a balanced distribution of "buy" and "sell" ratings across over 4,000 stocks, ensuring that only the top 5% receive a "Strong Buy" rating [10]. Veeva's Earnings Estimate Revisions - For the fiscal year ending January 2026, Veeva is expected to earn $7.59 per share, unchanged from the previous year, but analysts have raised their estimates by 6.4% over the past three months [9]. Conclusion - The upgrade to Zacks Rank 1 places Veeva in the top 5% of stocks covered by Zacks in terms of estimate revisions, suggesting potential for market-beating returns in the near term [11].

Core Viewpoint - CVB Financial (CVBF) has received an upgrade to a Zacks Rank 2 (Buy), indicating a positive outlook on its earnings estimates, which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Movement - The Zacks rating system is based on changes in earnings estimates, which are strongly correlated with near-term stock price movements [4][6]. - Institutional investors often rely on earnings estimates to determine the fair value of a company's shares, leading to buying or selling actions that affect stock prices [4]. Recent Performance and Outlook - For the fiscal year ending December 2025, CVB Financial is expected to earn $1.44 per share, unchanged from the previous year, but the Zacks Consensus Estimate has increased by 3.8% over the past three months [8]. - The upgrade to Zacks Rank 2 places CVB Financial in the top 20% of Zacks-covered stocks, suggesting potential for higher stock prices in the near term [10]. Zacks Rank System - The Zacks Rank system categorizes stocks into five groups based on earnings estimates, with a proven track record of generating significant returns for top-ranked stocks [7][9]. - Only the top 5% of stocks receive a "Strong Buy" rating, while the next 15% receive a "Buy" rating, indicating a balanced approach to stock ratings [9].

BioCryst Pharmaceuticals (BCRX) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the syst ...

Investors might want to bet on Hilltop Holdings (HTH) , as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.The power of a changin ...

Core Viewpoint - Candel Therapeutics, Inc. (CADL) has been upgraded to a Zacks Rank 1 (Strong Buy), indicating a positive outlook on its earnings estimates, which is a significant factor influencing stock prices [1][4]. Earnings Estimates and Revisions - The Zacks rating system is based on the Zacks Consensus Estimate, which reflects EPS estimates from sell-side analysts for the current and following years [2]. - Candel Therapeutics is expected to earn -$0.92 per share for the fiscal year ending December 2025, unchanged from the previous year, but analysts have raised their estimates by 17.5% over the past three months [9]. Impact of Institutional Investors - Changes in earnings estimates are strongly correlated with stock price movements, largely due to institutional investors who adjust their valuations based on these estimates [5]. - An increase in earnings estimates typically leads to higher fair value for a stock, prompting institutional investors to buy or sell, which in turn affects stock prices [5]. Zacks Rating System - The Zacks Rank stock-rating system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 stocks historically generating an average annual return of +25% since 1988 [8]. - Candel Therapeutics' upgrade to Zacks Rank 1 places it in the top 5% of Zacks-covered stocks, indicating strong potential for market-beating returns in the near term [11].

Core Viewpoint - ResMed (RMD) has been upgraded to a Zacks Rank 2 (Buy) due to an upward trend in earnings estimates, which is a significant factor influencing stock prices [1][3]. Group 1: Earnings Estimates and Stock Price Movement - The Zacks rating system is based on changes in a company's earnings picture, specifically tracking EPS estimates from sell-side analysts [1][2]. - A strong correlation exists between earnings estimate revisions and near-term stock price movements, making the Zacks rating system valuable for investors [4][6]. - Institutional investors utilize earnings estimates to determine the fair value of stocks, leading to buying or selling actions that affect stock prices [4]. Group 2: ResMed's Earnings Outlook - ResMed is projected to earn $9.48 per share for the fiscal year ending June 2025, indicating no year-over-year change [8]. - Over the past three months, the Zacks Consensus Estimate for ResMed has increased by 0.2%, reflecting a positive outlook for the company's earnings [8]. Group 3: Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 (Strong Buy) stocks historically generating an average annual return of +25% since 1988 [7]. - Only the top 20% of Zacks-covered stocks receive a "Strong Buy" or "Buy" rating, indicating superior earnings estimate revisions [9][10]. - ResMed's upgrade to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, suggesting potential for higher stock movement in the near term [10].

Solaris Energy Infrastructure, Inc. (SEI) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracke ...

Company Overview - Krystal Biotech, Inc. (KRYS) shares increased by 4.2% to close at $143.67, with trading volume significantly higher than usual, reflecting a 10.3% gain over the past four weeks [1][2] Product Development - The stock price surge followed the initiation of patient dosing in the phase III IOLITE study for KB803 eye drops, targeting DEB-related corneal damage, which is a next-generation version of the approved gene therapy Vyjuvek [2] - KB803 addresses a rare patient population lacking corrective treatments, and the decentralized, at-home study design, along with prior compassionate use data showing strong efficacy, has bolstered investor confidence [2] Financial Performance Expectations - The company is projected to report quarterly earnings of $1.31 per share, reflecting a year-over-year increase of 52.3%, with revenues expected to reach $102.5 million, up 45.9% from the previous year [3] - The consensus EPS estimate for the quarter has remained stable over the last 30 days, indicating that stock price movements may not sustain without trends in earnings estimate revisions [4] Industry Context - Krystal Biotech is categorized under the Zacks Medical - Biomedical and Genetics industry, where Coherus Oncology (CHRS) also operates, having closed 5.6% higher at $0.77, but with a -3.9% return over the past month [5] - Coherus Oncology's consensus EPS estimate for the upcoming report is -$0.25, representing a significant year-over-year decline of 78.6% [6]